Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - CBRNE - Incendiary Agents, Napalm : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
References

Related Articles
Burns, Thermal

Pediatrics, Pharyngitis

Pediatrics, Pneumonia

Pediatrics, Respiratory Distress Syndrome

Pharyngitis

Pneumonia, Bacterial

Respiratory Distress Syndrome, Adult

Sunburn

Toxicity, Hydrocarbons

Toxicity, Toluene




Patient Education
Bioterrorism and Warfare Center

Personal Protective Equipment




Author: Lisandro Irizarry, MD, MPH, FAAEM, Chair, Department of Emergency Medicine, Brooklyn Hospital Center; Assistant Professor, Department of Emergency Medicine, Weill Cornell School of Medicine

Lisandro Irizarry is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, American College of Medical Toxicology, and Society for Academic Emergency Medicine

Coauthor(s): Mollie V Williams, MD, Assistant Clinical Professor, Fellow in Disaster Preparedness, Department of Emergency Medicine, State University of New York Downstate Medical Center, Brooklyn; José Eric Díaz-Alcalá, MD, DABMT, Consulting Staff, Division of Emergency Medicine-Medical Toxicology, Department of Ambulatory Care, Veterans Affairs Medical Center of San Juan, Puerto Rico

Editors: Mark Keim, MD, Director, Emergency and Disaster Public Health Sciences, Adjunct Assistant Professor, Department of Emergency Medicine, Emory University, National Center for Environmental Health, Centers for Disease Control and Prevention; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; Robert G Darling, MD, FACEP, Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Director, Center for Disaster and Humanitarian Assistance Medicine

Author and Editor Disclosure

Synonyms and related keywords: naphthalene, palmitate, incendiary bomb, firebomb, land mine, flamethrower, napalm B, polystyrene, benzene, white phosphorus, thermite, trinitrotoluene, TNT, incendiary agent



Background

Napalm, invented by Fieser in 1942, is an incendiary substance made by the simple procedure of adding a "gelling" powder, composed of naphthalene and palmitate (hence "napalm"), to gasoline in varying concentrations to form a sticky, combustible substance.

This white, cloudy, jellylike substance has unique properties that render it an effective incendiary agent. Napalm is extremely stable, tolerating temperatures well above 150°F (effective in the tropics) and as low as -40°F (bomb shelters, cold weather environments). It is not shattered easily by explosives and can be stored for long periods without significant breakdown. Gelation of this substance occurs in 3-20 minutes. Gel formation enhances its effectiveness by allowing for a controlled, contained, and prolonged burn. Gelation also enhances its stability, with napalm requiring much higher temperatures to ignite than gasoline. There is no "off-sourcing" of hydrocarbon fumes associated with the nonignited compound. In fact, ignition requires the use of trinitrotoluene (TNT) to explode and ignite white phosphorus, the ignited temperature of which is high enough to result in the combustion of napalm.

Napalm has been used primarily in the form of incendiary bombs, firebombs, land mines, and flamethrowers. During World War II, firebombs, in the form of 165-gallon containers, were the primary method for the disbursement of napalm. One firebomb released from a low-flying airplane was capable of producing damage to a 2500-yd2 area. During the Korean War, the United States dropped approximately 250,000 pounds of napalm per day. Napalm's increased viscosity resulted in the enhanced effectiveness of flamethrowers, which were frequently used in World War II. Because of gasoline's increased instability, volatility, and its rapid burning and self-consumption, its effectiveness was limited to within 30 yards. Napalm, through its unique properties, extended the effective range of flamethrowers to 150 yards.

After World War II, the United States conducted an intensive effort to enhance the properties and effectiveness of napalm as an incendiary agent. This effort resulted in the development of napalm B (super napalm, NP2), which substituted polystyrene and benzene for naphthalene and palmitate. The resulting substance continued to bear the name napalm, although it lacked the 2 components of its namesake. Conventional napalm burns for 15-30 seconds, whereas napalm B burns for up to 10 minutes. Napalm B provided the United States with an incendiary substance with enhanced stability and controllability and, as such, became the weapon of choice during the Vietnam War. Such enhanced stability required an igniting agent such as white phosphorus, which burns at a higher temperature of 4532°F. White phosphorus replaced thermite, the ignitor previously used for traditional napalm.

Frequency

United States

Napalm has been used by the United States as recent as the Persian Gulf War.

Mortality/Morbidity

Morbidity and mortality are related directly to the extent of injuries received from trauma and extensive burns from exposure. No cases have been reported of systemic poisoning of individuals in contact with nonignited napalm.

German post-war estimates reveal approximately 25,000 deaths and 30,000 wounded individuals during a 2-day attack on Dresden, Germany, with the use of 3.4 kilotons of incendiary, half of which was napalm. According to a memorandum released by the Ministry of Foreign Affairs of the People's Republic of Korea, after the Korean War more than 10,000 napalm bombs were released during a 20-day period killing 12,000 individuals and wounding 2,500 others.1



History

  • Exposure history usually is obvious, with the individual recounting the sounds of an explosion and the unbearable pain associated with the burns of exposure.
  • Napalm produces carbon monoxide as a by-product of combustion. Thus, also evaluate individuals exposed to burning napalm for carbon monoxide exposure. In particular, consider individuals who are found with altered levels of consciousness near burning napalm to have been exposed to toxic levels of carbon monoxide until proven otherwise.

Physical

  • Immolation, asphyxiation, and burns are the mechanisms by which incendiary weapons kill or wound.
  • Immolation results in a rapid decrease in blood pressure leading to unconsciousness and death.
  • Asphyxiation usually occurs as a result of napalm ignition, which results in a rapid deoxygenation of surrounding air. This rapid deoxygenation results in an atmosphere of approximately 20% carbon dioxide.
  • Severe burns (second and/or third degree) are frequently found in areas exposed to burning napalm. Injuries related to the thermal elevation of the air temperature may result in respiratory embarrassment.
  • Burning napalm raises the ambient environmental temperature and has been known to cause the deaths of individuals in raid shelters as a result of radiant heat and dehydration. This was a frequent cause of death in the bombing raids carried out over Hamburg, Germany, during World War II. The result of this phenomenon frequently was referred to as Bombenbrandschrumpfleichen (incendiary-bomb–shrunken bodies).



Burns, Thermal
Pediatrics, Pharyngitis
Pediatrics, Pneumonia
Pediatrics, Respiratory Distress Syndrome
Pharyngitis
Pneumonia, Bacterial
Respiratory Distress Syndrome, Adult
Sunburn
Toxicity, Hydrocarbons
Toxicity, Toluene


Lab Studies

  • Patients exposed to napalm represent individuals with severe burns; perform laboratory evaluation as for any burn patient.



Prehospital Care

Give care to extinguishing flames and removing smoldering napalm from the skin. Remove contaminated clothing to prevent continued burning from hot napalm. If carbon monoxide exposure is a concern, provide 100% oxygen via a nonrebreather mask en route.

Emergency Department Care

Rapid intervention to stop cutaneous burning from napalm is of paramount importance. As with all burn patients, provide respiratory support and multiorgan evaluation.

  • Follow the standard ABC approach to resuscitation, paying special attention to respiratory evaluation, since patients may experience severe respiratory injury secondary to elevated ambient air temperature.
  • Perform full exposure and removal of the offending agent.
  • Evaluate burns and calculate the exposed area. This can be done by 1 of 2 common methods. The first involves using an affected individual's palmar surface, which roughly represents 1% body surface area (BSA) of that individual. The second uses the "rule of nines" method.
    • Percentage of BSA involved assists in determining disposition and/or transfer of the patient to a regional burn center. The American Burn Association has developed criteria for burn-center admission that include third-degree burns over 5% BSA; second-degree burns over 10% BSA; any second-degree and/or third-degree burns involving critical areas (eg, face, hands, feet, genitals); circumferential burns of the thorax or extremities; inhalational injuries; and significant chemical injuries, electrical burns, trauma, or significant preexisting medical conditions.
    • Base fluid resuscitation on the Parkland formula (2-4 mL/kg/h of intravenous crystalloid). Maintain urine output at 1-2 mL/kg/h.
  • Perform a full trauma evaluation because patients may sustain injury from percussion of blast or projectiles.
  • Take care to evaluate patients for carbon monoxide exposure.

Consultations

  • Consult the burn team for the evaluation and management of burns.
  • Consult the trauma team for the evaluation and management of traumatic injuries received as a consequence of explosions associated with napalm disbursement.



Implement medical therapy as indicated by the patient's medical condition. Remember to administer tetanus prophylaxis.

Drug Category: Toxoid

Toxoid is used for immunization; a booster injection in previously immunized individuals is recommended.

Drug NameTetanus toxoid
DescriptionUsed to induce active immunity against tetanus in selected patients. The immunizing agents of choice for most adults and children >7 y are tetanus and diphtheria toxoids. Necessary to administer booster doses to maintain tetanus immunity throughout life.
Pregnant patients should receive only tetanus toxoid not a diphtheria-antigen-containing product.
In children and adults, may administer into deltoid or midlateral thigh muscles. In infants, preferred site of administration is the mid thigh laterally.
Adult DosePrimary immunization: 0.5 mL IM; give 2 injections 4-8 wk apart; third dose 6-12 mo after second injection
Booster dose: 0.5 mL q10y
Pediatric DoseAdminister as in adults
ContraindicationsDocumented hypersensitivity; history of any type of neurologic symptoms or signs following administration; FDA recommends that elective tetanus immunization be deferred during any outbreak of poliomyelitis because tetanus toxoid injections are an important cause of provocative poliomyelitis
InteractionsPatients receiving immunosuppressants, including corticosteroids or radiation therapy, may remain susceptible despite immunization because of poor immune response; cimetidine may enhance or augment delayed-hypersensitivity responses to skin-test antigens; avoid concurrent use of medication with systemic chloramphenicol because it may impair amnestic response to tetanus toxoid; concurrent use of tetanus immune globulin may delay development of active immunity by several days (interaction nevertheless is clinically insignificant and does not preclude concurrent use)
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsDo not use to treat actual tetanus infections or for immediate prophylaxis of unimmunized individuals (use instead tetanus antitoxin, preferably human tetanus immune globulin); diminished antibody response to active immunization may be observed in patients receiving immunosuppressive therapy; better to defer primary diphtheria immunization until immunosuppressive therapy discontinued; routine immunization of symptomatic and asymptomatic HIV-infected persons is recommended

Drug Category: Analgesics

These agents ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who have sustained injuries.

Drug NameMorphine sulfate (Duramorph, Astramorph, MS Contin, MSIR, Oramorph)
DescriptionDOC for analgesia due to reliable and predictable effects, safety profile, and ease of reversibility with naloxone.
Various IV doses are used; commonly titrated until desired effect obtained.
Adult DoseStarting dose: 0.1 mg/kg IV/IM/SC
Maintenance dose: 5-20 mg/70 kg IV/IM/SC q4h
Relatively hypovolemic patients: Start with 2 mg IV/IM/SC; reassess hemodynamic effects of dose
Pediatric DoseInfants and children: 0.1-0.2 mg/kg dose IV/IM/SC q2-4h prn; not to exceed 15 mg/dose; may initiate at 0.05 mg/kg/dose
ContraindicationsDocumented hypersensitivity; hypotension; potentially compromised airway where establishing rapid airway control would be difficult
InteractionsPhenothiazines may antagonize analgesic effects of opiate agonists; TCAs, MAOIs, and other CNS depressants may potentiate adverse effects of morphine
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsAvoid in hypotension, respiratory depression, nausea, emesis, constipation, and urinary retention; caution in atrial flutter and other supraventricular tachycardias; has vagolytic action and may increase ventricular response rate

Drug NameMeperidine (Demerol)
DescriptionAnalgesic with multiple actions similar to those of morphine; may produce less constipation, smooth muscle spasm, and depression of cough reflex than similar analgesic doses of morphine.
Adult Dose50-150 mg PO/IV/IM/SC q3-4h prn
Pediatric Dose1-1.8 mg/kg (0.5-0.8 mg/lb) PO/IV/IM/SC q3-4h prn; not to exceed adult dose
ContraindicationsDocumented hypersensitivity; MAOIs; upper airway obstruction or significant respiratory depression; during labor when delivery of premature infant is anticipated
InteractionsMonitor for increased respiratory and CNS depression with coadministration of cimetidine; hydantoins may decrease effects of meperidine; avoid with protease inhibitors
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in patients with head injuries because meperidine may increase respiratory depression and CSF pressure (use only if absolutely necessary); caution when using postoperatively and with history of pulmonary disease (suppresses cough reflex); substantially increased dose levels, due to tolerance, may aggravate or cause seizures even if no history of convulsive disorders; monitor closely for morphine-induced seizure activity if seizure history

Drug Category: Nonsteroidal anti-inflammatory agents (NSAIDs)

These agents have analgesic, antiinflammatory, and antipyretic activities. Mechanism of action is not known but may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell-membrane functions, may exist as well.

Drug NameIbuprofen (Motrin, Ibuprin)
DescriptionDOC for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.
Adult Dose200-400 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d
Pediatric Dose<6 months: Not established
6 months to 12 years: 4-10 mg/kg/dose PO tid/qid
>12 years: Administer as in adults
ContraindicationsDocumented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding
InteractionsCoadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and possibly toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
PrecautionsCaution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy

Drug NameNaproxen (Aleve, Naprelan, Naprosyn, Anaprox)
DescriptionFor relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which results in a decrease of prostaglandin synthesis.
Adult Dose500 mg PO followed by 250 mg q6-8h; not to exceed 1.25 g/d
Pediatric Dose<2 years: Not established
>2 years: 2.5 mg/kg/dose PO; not to exceed 10 mg/kg/d
ContraindicationsDocumented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency
InteractionsCoadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and possibly toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently
PregnancyB - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
PrecautionsAcute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug

Drug Category: Topical antibiotics

Therapy must be comprehensive and cover all likely pathogens in the context of this clinical setting.

Drug NameNeomycin and polymyxin B (Neosporin)
DescriptionUsed in treatment of minor infections. Inhibits bacterial protein synthesis and growth. Polymyxin B disrupts bacterial cytoplasmic membrane, permitting leak of intracellular constituents and causing inhibition of bacterial growth.
Adult DoseApply qd/qid to affected areas
Pediatric DoseApply as in adults
ContraindicationsDocumented hypersensitivity
InteractionsNone reported
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in treating extensive burns (>20% BSA) because absorption of neomycin is possible and may cause nephrotoxicity and ototoxicity; prolonged use may result in overgrowth of nonsusceptible organisms

Drug NameSilver sulfadiazine (Silvadene, Thermazene, SSD, SSD-AF)
DescriptionUseful in prevention of infections from second-degree or third-degree burns. Has bactericidal activity against many gram-positive and gram-negative bacteria, including yeast.
Adult DoseApply qd/bid to a thickness of 1/16; burned area should be covered with medication continuously
Pediatric DoseApply as in adults
ContraindicationsDocumented hypersensitivity; neonates and infants <2 y
InteractionsEffect of proteolytic enzymes is reduced when used concomitantly with this product
PregnancyC - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
PrecautionsCaution in G-6-PD deficiency and renal insufficiency



In/Out Patient Meds

  • Administer medications as indicated by the patient's medical condition.

Transfer

  • If indicated, transfer patients to a regional trauma and/or burn center.

Prognosis

  • The prognosis is dictated by extent of physical injury, burns, and existing metabolic complications.

Patient Education



Medical/Legal Pitfalls

  • Legal issues are associated with inadvertent exposure to the ignited agent and to its inappropriate use (detonation) in situations other than wartime deployment.
  • Military personnel should be cognizant of the medical issues associated with exposure to ignited napalm and maintain an appropriate safe distance from any military use.



  1. Napalm. Globalsecurity.org. Available at http://www.globalsecurity.org/military/systems/munitions/napalm.htm. Accessed July 3, 2007.
  2. Bullens EF. Chemicals in combat. Armed Forces Chem J. 1952;5(4):4-7.
  3. Fieser LF. Napalm. Indust and Engin Chem. 1946;38:768-773.
  4. Harvey F. Air war in Vietnam. Flying. 1966;5:38-95.
  5. Hollingsworth EW. Use of thickened gasoline in warfare. Armed Forces Chem J. 1951;4(6):26-32.
  6. McLean AD. Burns and military clothing. J R Army Med Corps. Feb 2001;147(1):97-106. [Medline].
  7. Napalm. Wikipedia. Available at http://en.wikipedia.org/wiki/Napalm. Accessed July 3, 2007.
  8. Reich P, Sidel VW. Current concepts. Napalm. N Engl J Med. Jul 13 1967;277(2):86-8. [Medline].

CBRNE - Incendiary Agents, Napalm excerpt

Article Last Updated: Aug 22, 2007